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Adenosine monophosphate-activated protein kinase (AMPK) acts as a major sensor of cellular energy status in cancers and is
critically involved in cell sensitivity to anticancer agents. Here, we showed that AMPK was inactivated in lymphoma and related
to the upregulation of the mammalian target of rapamycin (mTOR) pathway. AMPK activator metformin potentially inhibited the
growth of B- and T-lymphoma cells. Strong antitumor effect was also observed on primary lymphoma cells while sparing normal
hematopoiesis ex vivo. Metformin-induced AMPK activation was associated with the inhibition of the mTOR signaling without
involving AKT. Moreover, lymphoma cell response to the chemotherapeutic agent doxorubicin and mTOR inhibitor temsirolimus
was signiﬁcantly enhanced when co-treated with metformin. Pharmacologic and molecular knock-down of AMPK attenuated
metformin-mediatedlymphomacell growth inhibition and drugsensitization. Invivo,metformininduced AMPKactivation, mTOR
inhibition and remarkably blocked tumor growth in murine lymphoma xenografts. Of note, metformin was equally effective when
given orally. Combined treatment of oral metformin with doxorubicin or temsirolimus triggered lymphoma cell autophagy and
functioned more efﬁciently than either agent alone. Taken together, these data provided ﬁrst evidence for the growth-inhibitory
and drug-sensitizing effect of metformin on lymphoma. Selectively targeting mTOR pathway through AMPK activation may thus
represent a promising new strategy to improve treatment of lymphoma patients.
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Incidence of lymphoma increases rapidly, ranking among the
tenth most commonly diagnosed cancer.
1 Relapsed from or
resistant to conventional chemotherapy, prognosis of the
patients, especially those with aggressive subtypes, remains
un-optimal. New regimens need to be investigated, particu-
larly those targeting signal transduction pathways on which
malignant lymphoma cells depend for their survival.
Accumulating evidence has linked tumor progression to
cellular metabolism, underscoring the possible therapeutic
strategy of targeting metabolic pathways in cancers.
2 Adeno-
sine monophosphate-activated protein kinase (AMPK) is the
main cellular energy sensor and actively participates in the
interaction between metabolism and cancer.
2 In normal
lymphocytes, AMPK controls cell survival, mediates cell
activation and metabolism.
3,4 However, the role of AMPK in
lymphoma is not clear. As mechanism of action, AMPK
activation regulates tumor cell growth through the inhibition of
the mammalian target of rapamycin (mTOR) pathway, which
is generally involved in the control of translation initiation and
protein synthesis.
5 Also critical in lymphocyte development,
6
mTOR is constitutively activated in various subtypes of
lymphoma and contributes to tumorogenesis and drug
resistance.
7–11 Whether therapeutic AMPK activation may
target mTOR signaling and lymphoma progression remains
great interest.
Metformin belongs to the biguanide class of oral hypogly-
cemic agents. Epidemiologic investigations reported that
metformintreatmentisassociatedwithadecreasedincidence





15 Experimental data conﬁrmed the inhibitory effect of
metformin on the growth of these tumor cells.
16–18 Clinically,
metformin improves outcome of diabetic cancer patients,
either alone or combined with chemotherapy, indicating its
potential role on cancer therapy.
19,20 In hematological
malignancies, recent update has demonstrated the activity
of metformin against acute myeloid leukemia, because of
AMPK-initiated mTOR inhibition.
21 However, the efﬁcacy of
this clinically available AMPK activator has never been
studied on lymphoma.
Autophagy is a cellular self-digestive process and of
fundamental importance in tissue homeostasis.
22 Although
autophagy is primarily a protective process for the cell, it can
also play a role in cell death.
23 The mTOR pathway regulates
cellautophagyunderstressconditions,especiallyresponseto
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24 Defect in autophagy has recently been
proposed to contribute to lymphoma progression,
24,25 and,
therefore, autophagy could be a promising target for
lymphoma treatment.
In this study, we reported the potent antitumor action of
AMPK activation in lymphoma. The AMPK activator metfor-
min induced a dose-dependent suppression of lymphoma cell
proliferation through negative control of the mTOR pathway.
Importantly, lymphoma cell sensitivity to anticancer agents
was enhanced by concomitant treatment of metformin via
induction of autophagy. Our results provided ﬁrst evidence for
the potential of therapeutic metformin/AMPK activation as a
novel approach for lymphoma treatment.
Results
The AMPK was inactivated in lymphoma and related to
the upregulation of the mTOR signaling pathway. To
examine the role of AMPK in human lymphoma, we ﬁrst
performed tissue array on primary tumor samples from 80
lymphoma patients (66 B-cell lymphoma, 10 T-cell lymphoma
and 4 Hodgkin’s lymphoma), using antibodies against
phosphorylated form of AMPK, mTOR and its downstream
effectors p70 ribosomal S6 kinase (p70S6K) and 4E-binding
protein 1 (4EBP1). As shown in Figure 1, the AMPK activity
was completely lost in lymphoma cells. Consistent with the
downregulation of AMPK expression, increased phospho-
rylation of mTOR, p70S6K and 4EBP1 were present in
77.3%, 66.7% and 69.7% of B-lymphoma cases, as well
as 90.0%, 90.0% and 80.0% of T-lymphoma cases,
respectively.
AMPK activator metformin inhibited lymphoma cell
proliferation. Using MTT assay, we then determined the
effect of AMPK activation on human B- and T-lymphoma cell
lines. Fifty percent of growth inhibition (IC50) was measured
in these cells treated with AMPK activator metformin.
Metformin exerted substantial growth inhibition in all
lymphoma cell lines examined at concentrations ranging
from 8.5 to 20.8mM (Figure 2a).
The dose-dependent response curves of two B cells (Daudi
and SU-DHL-4) and two T cells (HUT78 and Jurkat) were
shown in Figure 2b. Cell cycle was analyzed on these cells in
Figure 1 Dysregulation of AMPK/mTOR pathway in human lymphoma. Expression proﬁle of phosphorylated form of AMPK, mTOR, as well as its downstream effectors
p70S6K and 4EBP1 was assessed in human lymphoma tissue using tissue array. The melanoma tissue was served as the positive control of phosphorylated AMPK
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Cell Death and Diseasethe presence of metformin at 10mM. Comparing with the
control group (32.6±1.0% for Daudi and 33.5±4.6% for
SU-DHL-4 cells, respectively), the percentage of G0/G1 cells
were signiﬁcantly increased after metformin treatment for
36h (54.6±2.3% for Daudi and 47.8±1.0% for SU-DHL-4
cells, Po0.001 and Po0.01, respectively). Similar results
were also obtained in metformin-treated T-lymphoma cells
(45.9±5.9% versus 62.3±9.5%, Po0.05, for HUT78 cells,
and 44.5±1.9% versus 51.2±1.1%, Po0.01, for Jurkat
cells). Meanwhile, no signiﬁcant elevation of annexin
V-positive cells was found (data not shown). Western blot
analysis revealed that metformin stimulated phosphorylation
of AMPK and its downstream target acetyl-CoA carboxylase
(ACC)(Figure2c),indicatingthattheanti-proliferativeeffectof
metformin on lymphoma cells involved AMPK activation.
In primary lymphoma cells, metformin resulted in signiﬁcant
growth inhibition from the concentration of 10mM (Figure 2d).
However, proliferation of CD34þ cells isolated from human
cord blood, a population relatively enriched in hematopoietic
progenitor cells, was not affected even at the concentra-
tions up to 120mM, suggesting that metformin exerted no
major cytotoxic effect on normal hematopoietic precursors
(Figure 2e).
Metformin modulated the AMPK/mTOR axis without
involving AKT. On activation, AMPK inhibited the
phosphorylation of mTOR, p70S6K and 4EBP1 (Figure 3a).
To further determine if AMPK activation is responsible
for the effect of metformin, we used the speciﬁc AMPK
inhibitor compound C and the AMPK siRNA to block
AMPK expression in Jurkat cells. Both pharmacologic and
molecular knock-down of AMPK abrogated metformin-
induced lymphoma cell growth inhibition and cell cycle
arrest (Figures 3b and c). In addition to AMPK itself, AMPK
Figure 2 The inhibitory effect of metformin on growth of human lymphoma cell lines. (a)I C 50 results obtained from MTT assay in a series of B- and T-lymphoma
cell lines after metformin treatment. (b and c) Response curves (b) and AMPK/ACC expression detected by western blot (c) in malignant B and T cells treated with
metformin. (d) Metformin inhibited growth of primary lymphoma cells. (e) The proliferation of CD34þ cells enriched from cord blood samples was not altered by metformin
up to 120mM
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Cell Death and Diseasesilencing impaired the induction of ACC and inhibition of
mTOR by metformin (Figure 3c). These results suggested
that AMPK-initiated mTOR inhibition is essential for
metformin to impart its growth-suppressive effect in
lymphoma.
The mTOR inhibition may trigger a negative feedback loop,
resulting in the AKT upregulation.
26 When treated with
metformin, expression of phosphorylated AKT remained
constant (Figure 3d). Jurkat cells overexpressing AKT was
also sensitive to metformin (Figure 3e). These data supported
that metformin modulated AMPK/mTOR axis in an AKT-
independent manner.
Metformin blocked in vivo lymphoma growth. The in vivo
activity of metformin on lymphoma cells was also evaluated.
Subcutaneous inoculation of Daudi or Jurkat cells into nude
mice resulted in a tumor formation at the site of injection in all
mice. In these murine xenograft models of B- and T-cell
lymphoma, intraperitoneal treatment of metformin signiﬁ-
cantly inhibited tumor growth both in the low-dose and in
the high-dose group (Figure 4a).
Decreased tumor size following metformin treatment was
due to the reduced proliferation status of tumorcells as shown
by Ki-67 staining on mice tumor sections. Terminal deoxy-
transferase-catalyzed DNA nick-end labeling (TUNEL) assay
revealed no sign of lymphoma cell apoptosis. To search for
more evidence of AMPK/mTOR involvement, immunohisto-
chemical study of phosphorylated AMPK and mTOR were
performed. As compared with the control group, phosphoryla-
tion of AMPK was remarkably increased, with that of mTOR
decreased in the metformin group (Figure 4b).
Metformin acted together with the chemotherapeutic
agent to inhibit lymphoma growth through induction of
autophagy. Daudi and Jurkat cells were simultaneously
treated with metformin and doxorubicin, a standard chemo-
therapeutic agent for lymphoma therapy. Isobolographic
analysis yielded most of the data points within the envelope
of additivity, denoting additive interactions in both cell lines
(Figure 5a). AMPK knock-down by AMPK-a siRNA signiﬁ-
cantly decreased lymphoma cell response to metformin,
alone or combined with doxorubicin (Figure 5b). Interestingly,
expression of autophagy-related LC3-II was notably higher
in the combination group than in the single-agent group
at 72-h treatment (Figure 5c). The autophagy inhibitor
3-methyladenine signiﬁcantly rescued lymphoma cells from
the combined treatment, referring the growth-inhibitory effect
as autophagy speciﬁc (Figure 5d).
To determine the chemo-sensitizing effect of metformin
in vivo, we treated the xenograft models with metformin
Figure 3 Metformin-induced mTOR inhibition in an AMPK-dependent manner. (a) Metformin decreased the expression of phosphorylated mTOR, as well as its effectors
p70S6K and 4EBP1. (b and c) Speciﬁc AMPK inhibitor compound C (b) and AMPK siRNA (c) abrogated metformin-induced lymphoma cell growth inhibition and cell cycle
arrest. Comparing with the negative control (Con siRNA), Jurkat cells transfected with AMPK-a siRNA (AMPK siRNA) failed to induce phosphorylated ACC and inhibit
phosphorylated mTOR. *Po0.001 comparing with the metformin group.
þPo0.001 comparing with the Con siRNA group. (d) The expression of phosphorylated AKT
remained unchanged during metformin treatment in Jurkat cells. (e) Cell sensitivity to metformin was not affected in Jurkat cells transfected with AKT
Metformin/AMPK activation targeted lymphoma
W-Y Shi et al
4
Cell Death and Diseaseand/or doxorubin. Considering that clinical use of metformin
is typically performed by oral administration, and this would
be a preferred treatment option, metformin was at this time
given orally. As compared with either agent alone, dual treat-
ment was clearly more effective on tumor growth (Figure 5e).
Electron micrographic analysis showed that typical double-
membrane autophagic vesicles (autophagosomes) were most
frequently identiﬁed in the combination group, further conﬁrming
the increase in autophagy (Figure 5f).
Metformin potentiated the effect of the mTOR inhibitor to
induce lymphoma cell autophagy. The mTOR inhibitor
has recently been used to treat lymphoma.
11 We examined
the interaction of metformin with clinical relevant mTOR
inhibitor temsirolimus. In lymphoma cells, isobolographic
analysis also revealed an additive effect (Figure 6a), which
was signiﬁcantly reduced in lymphoma cells transfected with
AMPK-a siRNA (Figure 6b). The addition of metformin to
temsirolimus at 72h led to a remarkable increase in LC3-II
expression (Figure 6c). 3-methyladenine abrogated the
lymphoma cell growth inhibition, either induced by
metformin or in combination with temsirolimus (Figure 6d).
In vivo, the combined treatment of oral metformin and
temsirolimus inhibited tumor growth and augmented cell
autophagy in lymphoma-bearing mice, comparing with
individual drug treatments (Figures 6e and f).
Discussion
Metformin is the most widely used anti-diabetic drug in the
world, and there is increasing evidence of a potential efﬁcacy
of this agent as an anticancer drug.
27 Our study showed the
activity of metformin against lymphoma both in vitro and
in vivo. Importantly, metformin exerts a direct inhibitory effect
on lymphoma cells with a minimal degree of toxicity against
normal CD34þ hematopoietic precursors. Also the favorable
therapeutic index was conﬁrmed in murine lymphoma models
without apparent systemic toxicity, indicating that metformin
may be exploited for the management of lymphoma.
AMPK is a novel and biologically signiﬁcant participant with
a tumor-suppressor activity in the mitotic/cytokinetic phase of
the cell cycle.
28 The anti-lymphoma effect of metformin is
AMPK dependent. In addition to elevated AMPK expression
during metformin treatment, AMPK silencing using speci-
ﬁc AMPK inhibitor and AMPK-a siRNA counteracted the
metformin-induced inhibition of lymphoma cell growth and cell
cycle progression. It is recently reported that the interplay
between the AMPK-a subunit with the mitotic regulators in
the centrosome and midbody coordinate the fundamental
Figure 4 The effect of metformin in murine lymphoma xenograft models. (a) In both B- and T-cell lymphoma models, intraperitoneal treatment of metformin, both at the
high-dose (IP MET H) and low-dose (IP MET L) group, signiﬁcantly diminished xenograft tumor size. (b) As compared with the control group (Con), decreased proliferative
index Ki-67 was identiﬁed, while TUNEL staining was negative in the metformin group (MET). Immunohistochemical study showed increased numbers of cells positive for
phosphorylated AMPK, but decreased cells positive for phosphorylated mTOR in the metformin-treated tumors
Metformin/AMPK activation targeted lymphoma
W-Y Shi et al
5
Cell Death and Diseasebiological process of genome division during mitosis and
cytokinesis, and is closely related to the tumor-suppressive
property of AMPK.
28 More research is thus necessary to
clarify the precise mechanism linking metformin-mediated
AMPK activation to tumor cell cycle regulation.
Using tissue array, we conﬁrmed that mTOR is consistently




phosphorylated AMPK suppresses mTOR, as well as its
downstream effectors p70S6K and 4EBP1, ultimately inhibit-
ingcellgrowth.
29ThemTORinhibitors,althoughalreadybeen
developed as anti-lymphoma therapies in clinical trials, are
hampered because of the induction of multiple resistance
mechanisms, particularly feedback activation of AKT. Moreover,
recent study showed that rapamycin fails to block the expres-
sion of oncogenic proteins in acute myeloid leukemia, which is
caused by the persistence of highly phosphorylated 4EBP1
molecules that maintain translation initiating complexes in
active conﬁguration in rapamycin-treated leukemia cells.
21 New
approach should thus be considered to bypass these processes.
Here, we found that metformin was not altered by AKT upregu-
lation, and could signiﬁcantly downregulate phosphorylated
4EBP1. Of note, metformin enhanced the lymphoma cell
sensitivity to the mTOR inhibitor, further indicative of an
important role of metformin on mTOR-activated lymphoma.
Metformin potentiated the effect of chemotherapy in
lymphoma. Experimental data on the solid tumor showed that
Figure 5 Metformin enhanced lymphoma cell sensitivity to the chemotherapeutic agent and stimulate autophagy. (a) In Daudi and Jurkat cells, metformin increased the
cytotoxicityof thechemotherapeuticagent doxorubicin.(b) Metformincombinedwith doxorubicininducedlesslymphomacell growth inhibitionin theAMPKsiRNA groupthan
intheConsiRNAgroup,*Po0.001comparingwiththeConsiRNAgroup.(c)Autophagy-relatedLC3-IIexpressionwassigniﬁcantlyelevatedincellsco-treatedwithmetformin
and doxorubicin. (d) Autophagy inhibitor 3-methyladenine abrogated lymphoma cell growth inhibition induced by co-treatment. (e) Combined oral metformin with doxorubicin
signiﬁcantly inhibited xenograft lymphoma growth, comparing with the control group or each agent alone. (f) The metformin/doxorubicin combination frequently induced
lymphoma cell autophagy
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Cell Death and Diseasemetformin signiﬁcantly inhibited proliferation of chemo-resis-
tant cells, inducing cell cycle arrest accompanied by attenu-
ated mTOR activation.
30 Clinically, retrospective analyses
suggested that metformin may improve patient response
following neo-adjuvant chemotherapy for breast cancer.
20
Our in vitro study demonstrated that metformin, beginning
from a relatively lower dose (1.25mM), worked together with
the chemotherapeutic agent in lymphoma. Correspondingly,
in vivo tumor-inhibitory effect of doxorubicin was enhanced by
metformin treatment. Oral metformin is equally effective, with
the concentration used in xenograft experiments roughly
comparabletowhatisusedtotreathumanpatientswithtypeII
diabetes.
31 Based on the fact that the therapeutic advantage
oforalmetforminisrelatedtoitsabilitytoselectivelykillcancer
stem cells,
31 these ﬁndings further support the role of
metformin in combination with chemotherapeutic agents that
primarily target non-stem cancer cells.
Metformin targets tumor cells by different mechanisms.
Not only it can amplify chemotherapy-induced AMPK activa-
tion and induces tumor cell apoptosis,
32 but also inhibit
tumor development through autophagy.
33 Autophagy is an
apoptosis-alternative pathway to induce cell death. Activation
of autophagy improves the chemo-sensitizing effect of
anticancer agents.
34 In lymphoma, defect in autophagy
correlates with a poor prognosis and less responsive to
chemotherapy.
25 Activation of AMPK could inhibit mTOR,
the negative regulator of autophagy and then stimulates
autophagy.
35 Here, we found that metformin treatment
enhanced tumor cell response to doxorubicin in murine
lymphoma models in concert with increased autophagy in
Figure 6 Metformin potentiated the effect of mTOR inhibitor to induce lymphoma cell autophagy. (a) In Daudi and Jurkat cells, metformin enhanced the growth-inhibitory
effect of the mTOR inhibitor temsirolimus. (b) Metformin combined with temsirolimus induced less lymphoma cell growth inhibition in the AMPK siRNA group than in the Con
siRNA group, *Po0.001 comparing with the Con siRNA group. (c) Co-treatment resulted in LC3-II upregulation. (d) Lymphoma cell growth inhibition was overcome by
autophagy inhibitor 3-methyladenine. (e) Combined oral metformin with temsirolimus signiﬁcantly inhibited xenograft lymphoma growth, comparing with the control group or
each agent alone. (f) The metformin/temsirolimus combination frequently induced lymphoma cell autophagy
Metformin/AMPK activation targeted lymphoma
W-Y Shi et al
7
Cell Death and Diseasethose tumors. This revealed a novel biological function
for metformin to enhance the cytotoxic action of chemo-
therapeutic agents.
In conclusion, mTOR pathway dysregulation in lymphoma
could be targeted by AMPK, providing a successful metabo-
lism-regulating model for inhibition of tumor cell growth.
Therapeutic metformin/AMPK activation, generally con-
sidered safe, well tolerated and remarkably inexpensive,
offers great promise for lymphoma treatment.
Materials and Methods
Cells. The B-lymphoma cell lines (SU-DHL-4, Nalmawa, DB, SU-DHL-5 and
Daudi) and T-lymphoma cell lines (Jurkat, 6T-CEM, Kappas, H9 and HUT78) are
available from American Type Culture Collection (Bethesda, MD, USA). CD34þ
cells were isolated from human cord blood using CD34 Progenitor Cell Isolation Kit
(Miltenyi Biotech Inc., Auburn, CA, USA). Fresh lymphoma cells from the lymph
node of three lymphoma cases were also obtained. Cells were maintainedin RPMI-
1640 medium supplemented with 10% heat-inactivated fetal bovine serum in a
humidiﬁed atmosphere of 95% air and 5% CO2 at 371C. All biological studies were
approved by the Institutional Review Board and informed consent was obtained in
accordance with the Declaration of Helsinki.
Reagents. Metformin (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in
phosphate-buffered saline (PBS) as a stock solution of 100mM. Antibodies against
phosphorylated ACC, ACC, phosphorylated AMPK, AMPK, phosphorylated mTOR,
mTOR, phosphorylated p70S6K, p70S6K, phosphorylated 4EBP1, 4EBP1,
phosphorylated AKT, AKT, LC3-II and chemiluminescence phototope-horseradish
peroxidasekitwerepurchasedfromCellSignaling(Beverly,MA,USA).Horseradish
peroxidase-conjugated goat anti-mouse IgG and goat anti-rabbit IgG were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-glyceraldehyde phosphate
dehydrogenase (GAPDH) antibody was from Sigma-Aldrich. The AMPK inhibitor
compound C and the autophagy inhibitor 3-methyladenine were from Merck KGaA
(Darmstadt, Germany).
Cell proliferation assay. Cells were seeded in 96-well plates and incubated
in the presence of solvent control or the indicated concentrations of agents at 371C
for 72h. Cell proliferation was assessed by MTT assay and the absorbance was
measured at 570nm by spectrophotometry.
Flow cytometric assay. To assess the distribution of nuclear DNA content,
cells were ﬁxed overnight in 75% ethanol at  201C, treated with 1% RNaseA for
15min at 371C and stained with 50mg/ml propidium iodide. Cell apoptosis was
analyzed using an ApoAlert Annexin V-FITC Apoptosis kit (Clontech, Palo Alto,
CA, USA) according to the manufacturer’s instructions. The ﬂuorescent intensity
was measured by ﬂow cytometry.
Cell transfection. Jurkat cells were transfected with siRNAs targeting the
AMPK-a1anda2subunit(Invitrogen,LifeTechnologies,GrandIsland,NY,USA),or
a control siRNA using AMAXA nucleofector Kit V following the manufacturer’s
instruction (AMAXA Biosystems, Cologne, Germany). Jurkat cells were also
transfected with pcDNA3 Myr HA AKT1 (Addgene Inc., Cambridge, MA, USA) or a
controlvectorpcDNA3,andelectroporatedat200V25msin4-mmcuvettesusinga
BTX ECM 830.
Western blot. Cells were lysed in 200ml lysis buffer (0.5M Tris-HCl, pH 6.8,
2mM EDTA, 10% glycerol, 2% SDS and 5% b-mercaptoethanol). Protein extracts
(20mg) were electrophoresed on 10% SDS polyacrylamide gels and transferred to
nitrocellulosemembranes.Membraneswereblockedwith5%non-fatdriedmilkinTris-
buffered saline and incubated for 2h at room temperature with appropriate primary
antibody, followed by horseradish peroxidase-conjugated secondary antibody. The
immunocomplexes were visualized using chemiluminescence phototope-horseradish
peroxidase kit. GAPDH was used to ensure equivalent protein loading.
Immunohistochemistry. Immunohistochemical analyses were carried out
on 5-mm parafﬁn sections with an indirect immunoperoxidase method using
antibodies against phosphorylated AMPK at 1:100 dilution, phosphorylated mTOR
(Epitomics Inc., Burlingame, CA, USA) at 1:50 dilution, phosphorylated p70S6K at
1:60 dilution, phosphorylated 4EBP1 (Epitomics Inc.) at 1:100 dilution and Ki-67
(Dako, Glostrup, Denmark) at 1:100 dilution.
TUNEL assay. In situ cell apoptosis was conﬁrmed by detection of fragmented
DNA, using TUNEL assay, on 5-mm parafﬁn sections, using DeadEnd Colorimetric
TUNEL System (Promega Corporation, Madison, WI, USA) according to the
manufacturer’s instruction.
Tissue array. A human lymphoma tissue array (LM802) was purchased from
USBiomax,Inc. (Rockville,MD,USA)and analysiswas conductedaccordingto the
manufacturer’s suggested protocols. The melanoma tissue was served as the
positive control for phosphorylated AMPK detection. Protein expression levels were
scored semi-quantitatively based on staining intensity (SI) and distributionusing the
immunoreactive score (IRS). Brieﬂy, IRS ¼ SI PP (percentage of positive cells).
SI was determined as 0¼negative; 1¼weak; 2¼moderate; and 3¼strong.
PP was deﬁned as 1, o25%; 2, 25–50%; 3, 50–75%; and 4, 75–100% positive
cells. IRS Z4 was referred as positive.
Transmission electronmicroscopy. Micelymphoma sampleswere ﬁxed
overnight in 2% glutaraldehyde at 41C, rinsed with 0.1M cacodylate buffer,
postﬁxed in 1% osmium tetroxide for 1h at 41C, dehydrated in graded ethanol and
embeddedin Epon812(TAABLaboratories,Berkshire,UK). Ultrathin sectionswere
prepared, stained with uranyl acetate and lead citrate, and examined on PhilipsCM120
transmission electron microscope (Eindhoven, The Netherlands). Ultrastructural studies
were focused on double membrane-bound autophagic vesicles named autophago-
somes, a long-established analytic gold standard for autophagy.
Tumor models. Two murine xenograft lymphoma models were applied to test
the in vivo efﬁciency of metformin. Brieﬂy, nude mice (5 to 6 weeks old, Shanghai
Laboratory Animal Center, Shanghai, China) were injected into the right ﬂank with
1 10
7 Daudi cells (mice received 300cGy for lymphoma cell engraftment) or
4 10
7Jurkatcells,allofwhichdevelopedtumorsin2weeks.Treatments(sixmice
per group) were started after tumor became about 0.5cm 0.5cm in surface
(day0).Forintraperitonealuse,themicewererandomlytreatedwithPBS,low-dose
(2mg/kg/day) or high-dose metformin (4mg/kg/day) for 21 days. For oral use, the
mice were randomly treated for 2 weeks with PBS, oral metformin (3mg/kg/day),
intraperitonealdoxorubicin(3mg/kg/day,twiceweekly),intraperitonealtemsirolimus
(5mg/kg/day every other day) or the combination treatment, respectively. Tumor
volumeswerecalculatedas0.5 a b
2,where‘a’ isthelengthand‘b’isthewidth.
All the mice experiments were performed in accordance with Institutional animal
care and use committee procedures and guidelines.
Isobolographic analysis. Determination of the synergistic versus additive
versus antagonistic-inhibitory effects of treatment combination was made using the
isobologram of Steel and Peckham. On the basis of dose-response curves of the
two drugs, three isoeffect curves were constructed. The area surrounded by the
isoeffect curves was referred as the envelope of additivity. When the data points of
thetreatmentcombinationfellwithintheenvelope,thecombinationwasregardedas
additive.
Statistical analysis. Assays were set up in triplicates and the results were
presented as mean±S.D. Variance between the experimental groups were
determined by two-tailed t-test. Po0.05 was considered statistically signiﬁcant.
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